logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Durvalumab in addition to platinum based chemoradiation therapy for treating non-small-cell lung cancer

< Back

Durvalumab in addition to platinum based chemoradiation therapy for treating non-small-cell lung cancer

Drugs

Cancer and Palliative Care

October 2020


Durvalumab in addition to platinum-based chemoradiation therapy (CRT) is in development for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC). Locally advanced (stage III) lung cancer refers to when the cancer has spread to lymph nodes and tissues near the lung that was initially affected but not to other areas of the body. The prognosis for unresectable, stage III NSCLC remains poor so there is a need for additional treatment options to improve overall survival rates.
Durvalumab is given by intravenous infusion and works by blocking an immune protein called programmed cell death ligand-1 (PD-L1). PD-L1 expression enables cancer cells to avoid recognition by the immune system. By blocking PD-L1, durvalumab allows the immune system to recognise and target the cancer cells. Addition of durvalumab to the current CRT treatment is thought to be more effective and improve overall survival rates compared to CRT alone. If licenced, durvalumab in addition to CRT may provide an additional treatment option for patients with unresectable, locally advanced NSCLC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts